Eli Lilly (LLY): The Drug Companies Never Learn

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

At least once a year, and probably more often, a big drug company makes a settlement or faces suits over not disclosing the bad effects of one or more of its products.

Lilly’s anti-psychotic drug Zyprexa can cause severe weight gain which can lead to diabetes. Investigators clearly think that someone at Lilly knew this. As The Wall Street Journal points out "the prospect of an indictment is daunting for a drug maker in light of the government’s huge role in health care, since a criminal finding could compromise a company’s access to government business."

Lilly may pay as much as $1 billion to settle with the feds and state governments. Then all of its Zyprexa problems will go away like bad dreams.

The settlement hardly gets to the heart of the matter which is that drug companies appear to be routinely prepared to be overly aggressive in marketing their products. Lawsuits are part of the cost of doing business. Lilly made over $1 billion last quarter. The charge for settling this matter will probably be spread over more than one year.

The drug company culture is deeply flawed and undermined by an acceptance of deception. Prosecutors and the FDA know that. But, they seem not to be willing to do much about it.

Douglas A. McIntyre

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618